



Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings

FREMONT, Calif., April 15 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX) today announced upcoming presentations of clinical and preclinical data from studies of panitumumab, a fully human monoclonal antibody currently in pivotal clinical trials as a third line monotherapy in colorectal cancer, will be presented at the American Association for Cancer Research (AACR) annual meeting April 16-20 in Anaheim, California and the 41st American Society of Clinical Oncology (ASCO) annual meeting May 13-17 in Orlando, Florida.

AACR The following abstracts are being presented at the AACR meeting:

- "Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Xenograft Models -- A 'Balanced' Approach" will be presented in the Cellular and Molecular Biology 1, Expression Profiling and Analysis of Cancer Biology session on Sunday, April 17 from 8:00 a.m. to 12:00 p.m. (Abstract #1);
- "Activity of Panitumumab Against Mutant and Wild Type EGFr NSCLC Cell Lines and Xenografts" will be presented in the Molecular Biology 56 session on Tuesday, April 19 from 1:00 PM to 5:00 PM (Abstract #4494); and
- "Identification and Preclinical Characterization of EGFr Somatic Gene Mutations from a Panitumumab Phase 2 NSCLC Clinical Trial: Discovery of a Novel Mutation with Panitumumab Sensitivity and Gefitinib Resistance" will be presented in the Late-Breaking Poster session Tuesday, April 19 from 1:00 p.m. to 5:00 p.m. (Abstract #LB205).

ASCO The following abstracts will be presented at ASCO in May:

- "Updated Results from a Dose and Schedule Study of Panitumumab (ABX-EGF) Monotherapy, in Patients with Advanced Solid Malignancies" will be presented on Sunday, May 15 from 8:00 a.m. to 12:00 p.m. during the General Poster Session; and
- "Safety and Efficacy of Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer (mCRC)" will be presented during a Poster Discussion on Tuesday May 17 from 8:00 a.m. to 12:00 p.m.

About Panitumumab

Co-developed by Amgen and Abgenix, panitumumab is an investigational product in a novel class of targeted cancer treatments called epidermal growth factor receptor (EGFr) inhibitors. Panitumumab (formerly ABX-EGF) is the first fully human monoclonal antibody directed against EGFr and is being evaluated as both a monotherapy and in combination with other agents for the treatment of various types of cancer, including colorectal, lung and kidney. Panitumumab is generated with Abgenix's XenoMouse(R) technology, which creates a fully human monoclonal antibody that contains no murine (mouse) protein. The fully human nature of panitumumab may result in a favorable safety profile with a low incidence of infusion reactions, antigenicity and allergic response. These are attributes currently being investigated in clinical trials. Pivotal clinical studies evaluating panitumumab as a third-line monotherapy in colorectal cancer patients are ongoing with a convenient every-other-week dosing regimen.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through its own development efforts and the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

Certain statements in these materials, including information presented in the letter to stockholders, are forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include forward-looking statements about Abgenix's technologies, product development activities, clinical trials and clinical trial results, the potential submission of a biologic license application for panitumumab, collaborative arrangements, process sciences and manufacturing activities, projected financial and operating results, and achievement of milestone or similar payments or other revenues. All such statements are subject to a number of uncertainties that could cause actual results to differ materially from the statements made,

including risks associated with conducting clinical trials, regulatory approval processes and meeting requirements for regulatory approval, the progress of research and product development programs, product manufacturing, competitive products and services, capital requirements, the extent and breadth of Abgenix's patent portfolio, and other factors set forth in Abgenix's public filings with the Securities and Exchange Commission. The forward-looking statements included in these materials are made only as of the date of publication and Abgenix does not undertake any obligation to update any forward-looking statements.

SOURCE Abgenix, Inc.

04/15/2005

CONTACT: Ami Knoeffler, Senior Director, Corporate Communications and Investor Relations, of Abgenix, Inc., +1-510-284-6350, or +1-510-284-6605

Web site: <http://www.abgenix.com>